These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 16905682)

  • 1. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
    Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
    J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations.
    Pollock PM; Spurr N; Bishop T; Newton-Bishop J; Gruis N; van der Velden PA; Goldstein AM; Tucker MA; Foulkes WD; Barnhill R; Haber D; Fountain J; Hayward NK
    Hum Mutat; 1998; 11(6):424-31. PubMed ID: 9603434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
    Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
    Goldstein AM
    Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
    Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
    J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CM-Score: a validated scoring system to predict
    Potjer TP; Helgadottir H; Leenheer M; van der Stoep N; Gruis NA; Höiom V; Olsson H; van Doorn R; Vasen HFA; van Asperen CJ; Dekkers OM; Hes FJ;
    J Med Genet; 2018 Oct; 55(10):661-668. PubMed ID: 29661971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
    Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
    J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.